THE ADDED VALUE OF STATE-OWNED HOSPITALS IN CONDUCTING CLINICAL TRIALS
DOI:
https://doi.org/10.15547/tjs.2025.02.007Keywords:
COVID-19 pandemic, trial protocol, BulgariaAbstract
Objective: The object of the article is to review the clinical trials conducted in Bulgarian state-owned hospitals during the COVID-19 pandemic (2019-2022). Material and methods: We have created a unique database of clinical trials from public registers of competent authorities. Our review is based on the content of the protocols of 550 clinical trials conducted in all 62 state-owned hospitals. Results: The number of clinical trials is decreasing, as is the number of trial centres in state-owned hospitals. The clinical trial sector will not go back to pre-pandemic levels, as we predict for the year after the pandemic (2023). In the new reality, reduced budget and declined state funding, the attitudes of state-owned hospitals and patients are shifting towards the benefits of clinical trials. The primary motive for state-owned hospitals to conduct clinical trials is not revenues, but rather access to new drugs and treatment methods. Conclusions: We explain the decline in the number of clinical trials with the national measures addressed to the challenges of the COVID-19 pandemic. The therapeutic area of clinical trials is tailored to the local demographic trend and is not aligned to the most common diseases in Bulgaria. Therefore, Bulgaria is more of a market for the launching tested drugs than a market for testing new drugs.
References
Dimova A, Rohova M, Koeva S, Atanasova E, Koeva-Dimitrova L, Kostadinova T, Spranger A, Polin K. Bulgaria: Health System Summary, 2022. WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies. Copenhagen, 2022.
Ministry of Health. Medical-statistical and financial information. Sofia, 2023.
OECD/European Observatory on Health Systems and Policies. Bulgaria: Country Health Profile 2023, State of Health in the EU. OECD Publishing, Paris/European Observatory on Health Systems and Policies. Brussels, 2023.
Mitkova Z, Doneva M, Gerasimov N, Tachkov K, Dimitrova M, Kamusheva M, Petrova G. Analysis of Healthcare Expenditures in Bulgaria. Healthcare (Basel), 10(2):274, 2022.
German-Bulgarian Chamber of Industry and Commerce. Pharmaceutical Industry in Bulgaria. Sofia, 2021.
International Trade Administration. Bulgaria – Healthcare and Life Sciences. Washington, DC, 2024.
Advisen. Clinical Trial Research in Hospitals. New York, 2012.
Public Enterprises and Control Agency. Annual summary report on state-owned public enterprises for 2021. Sofia, 2022.
Gergova V, Serbezova A, Sidjimova D. Analysis on decentralized clinical trials in some European countries. Archives of the Balkan Medical Union, 56(4):394-401, 2021.
Georgiev K, Kirilov B, Georgieva M. Pharmacological features of drugs with potential activity against COVID-19. Pulmonology Science, 1: 11-18, 2020.
European Commission. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. Brussel, 2022.
Organisation for Economic Co-operation and Development. OECD Guidelines on Corporate Governance of State-Owned Enterprises. Paris, 2015.
Bulgarian Drug Agency. Register of Authorised Clinical Trials. Sofia, 2025.
European Medicines Agency. European Union Clinical Trials Register. Amsterdam, 2025.
Bartoszkiewicz M, Kufel-Grabowska J, Litwiniuk M. Number of clinical trials of new therapeutic agents in the European Union countries of Central and Eastern Europe, 2000-2019. Polish Annals of Medicine, 29(1):26-30, 2022.
Dimova A, Rohova M, Polin K. Bulgaria: Health System Summary, 2024. European Observatory on Health Systems and Policies. Copenhagen, 2024.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
